BioFocus DPI is the service division of Galapagos NV, an integrated drug discovery company, quoted on Euronext Brussels (ticker symbol: GLPG) and Amsterdam (GLPGA) and the OTC Pink Sheets (GLPYY). 

Galapagos is committed to finding novel and effective drugs to treat bone and joint diseases and in providing quality service and products to advance its partners’ drug discovery programs. The Company has a strong team of first-class researchers that drive the innovative approach to identification of novel drug targets and the development of candidate drugs. The Company’s strong investor base have a long term commitment to the biotech industry. For more investor information, please follow this link to Galapagos’ Investor Relations Center

To receive an investor pack or a copy of the Galapagos prospectus, please contact the Investor Relations team.